目的：对2012～2021年国际发表的干细胞治疗缺血性脑卒中的文献进行可视化分析。方法：以Web of Science 引文索引数据库的核心合集为数据来源，利用CiteSpace软件对2012～2021年干细胞与缺血性 脑卒中研究的相关文献进行年发文量、国家、机构、作者、文献共被引和关键词等可视化分析。结果：共纳 入1 941篇文献，美国和中国分别是该领域发文最高的国家，代表机构是美国的佛罗里达大学和中国的上 海交通大学。发文数量最多的作者是来自南佛罗里达大学医学院教授CESAR V BORLONGAN团队。间 充质干细胞、移植、神经干细胞、动物模型、功能恢复、再生医学、纳米材料等是该领域的研究热点。时区分 析得知，发展前期以间充质干细胞、神经干细胞、骨髓基质细胞等不同种类细胞的作用机制研究为主，发展 中期以细胞植入、卒中后功能障碍的恢复为主，发展后期到迄今的研究阶段以药物输送、免疫治疗和纳米 医学研究为主。结论：干细胞治疗缺血性脑卒中在未来的发展前景广阔。

A visual analysis of the internationally published literature on stem cell therapy for ischemic stroke between 2012 and 2021 was performed. Methods: The core collection of Web of Science citation index database was used as the data source, and CiteSpace software was used to make a visual analysis of the literature related to stem cell and ischemic stroke between 2012 and 2021 in terms of annual number of publications, country, institution, author, co-citation, and keywords. Results: A total of 1 941 articles were included. The United States and China were the countries with the highest number of publications in this field, and the representative institutions were the University of Florida in the United States and Shanghai Jiao Tong University in China, respectively. The most prolific team was the one led by Prof. Cesar V Borlongan, a professor at the University of South Florida College of Medicine. Mesenchymal stem cells, transplantation, neural stem cells, animal models, functional recovery, regenerative medicine, and nanomaterials were the research hotspots in this field. According to the time series analysis, research on the action mechanisms of different types of cells, such as mesenchymal stem cells, neural stem cells, and bone marrow stromal cells was mainly conducted in the early stage of development; research on implantation of stem cells and recovery of post-stroke dysfunction was mainly conducted in the middle stage of development; the research on drug delivery, immunotherapy, and nanomedicine has been focused on from the late stage to the present. Conclusion: Stem cell therapy for ischemic stroke has broad prospects in the future.